Bengaluru-based direct-to-consumer (D2C) orthopaedic products startup Lumov is in talks to raise approximately ₹33 crore in a funding round led by Peak XV Partners’ Surge programme, as investors increasingly explore opportunities in India’s healthcare, rehabilitation and consumer medical products markets. Existing investors are also expected to participate in the proposed round, which could provide fresh capital for the startup’s expansion and product development.
Founded in 2024, Lumov develops orthopaedic braces, rehabilitation aids and products designed for post-surgical recovery and pain management. The startup is building a consumer-focused brand around orthopaedic care, combining product design, clinical collaboration and online distribution to address demand for recovery and mobility products in India.
Lumov in Talks to Raise ₹33 Crore
Lumov is looking to raise around ₹33 crore, or approximately $3.5 million, in a funding round led by Peak XV Partners’ Surge programme, according to reports citing sources familiar with the matter.
The startup’s existing investors are also expected to participate in the round. However, the proposed investment had not been officially confirmed by Lumov or Peak XV at the time of reporting.
The funding could help Lumov scale operations, expand distribution, strengthen its product portfolio and invest in manufacturing capabilities as it seeks to build a larger presence in India’s orthopaedic products market.
The proposed round follows the startup’s earlier seed funding, which helped it establish its initial product portfolio and build partnerships with healthcare professionals.
What Lumov Does
Lumov focuses on orthopaedic products designed to support people recovering from injuries, surgeries and musculoskeletal conditions.
Its product portfolio includes:
- Knee braces and support products
- Lower-back support belts
- Orthopaedic insoles
- Rehabilitation and recovery aids
- Products designed to support mobility and pain management
The company aims to provide products that combine functional support, comfort and design, targeting consumers who need orthopaedic support outside hospital settings.
Its products are sold through its own digital channels as well as online marketplaces, including Flipkart and Blinkit, allowing the brand to reach consumers looking for healthcare-related products through ecommerce and quick-commerce platforms.
Founded by Former Private Equity Professionals
Lumov was founded by Saumaric Dangwal and Ankit Gupta, who bring experience in investment and financial services to the startup.
Dangwal previously worked with Bain Capital, focusing on healthcare and consumer investments, while Gupta has been associated with Brookfield Private Equity and Steinberg Asset Management.
The founders are building Lumov around their understanding of healthcare, consumer markets and the opportunity to develop specialised products for India’s orthopaedic and rehabilitation needs.
The company is seeking to bridge the gap between basic low-cost orthopaedic products and expensive international alternatives by offering products developed with a focus on Indian consumers.
Clinical Partnerships Support Product Development
Lumov says it works with orthopaedic specialists to develop products suited to patient needs, recovery requirements and local conditions.
The startup has cited collaborations with specialists associated with hospitals including Manipal Hospitals, Apollo Hospitals, Sakra World Hospital and AIG Hospitals.
Clinical collaboration can help orthopaedic product companies understand how patients use support devices during recovery, rehabilitation and everyday activities.
The category requires careful product design because braces, insoles and other support products need to balance stability, comfort, durability and ease of use.
Lumov’s approach is aimed at developing products that can be used outside hospitals and clinics, potentially allowing consumers to access recovery and mobility solutions through retail and digital channels.
Previous $1.2 Million Seed Funding
Lumov previously raised approximately $1.2 million, or around ₹10 crore, in a seed funding round led by Incubate Fund Asia in December 2025.
The round also included participation from QRG Investments and Holdings, IIMA Ventures, SIDBI and several angel investors.
The company planned to use the funding to strengthen manufacturing, expand its sales operations, develop new products and deepen relationships with orthopaedic surgeons.
It also planned to expand its presence in markets such as Delhi NCR, Hyderabad and Mumbai.
The proposed ₹33 crore round would give Lumov additional capital to pursue these ambitions and potentially accelerate its expansion into a broader orthopaedic and musculoskeletal care product business.
India’s Orthopaedic and Rehabilitation Market Opportunity
India’s orthopaedic and rehabilitation market is supported by several long-term trends, including an ageing population, sedentary lifestyles, increasing sports participation, rising injuries and growing demand for post-surgical recovery support.
Musculoskeletal problems involving bones, joints, muscles and ligaments can create demand for braces, mobility aids, orthotic products, rehabilitation equipment and pain-management solutions.
However, the market remains fragmented, with products distributed through medical stores, hospitals, online marketplaces and specialised healthcare retailers.
Consumers are increasingly discovering medical and recovery products through digital platforms, creating an opportunity for companies to build recognisable brands in categories traditionally dominated by unbranded or specialised medical equipment.
Lumov is attempting to use this shift to build a consumer-facing business around orthopaedic support products, while improving product design, accessibility and brand awareness.
Why Investors Are Interested in Consumer Healthcare
Consumer healthcare and specialised medical products are attracting investor attention because they combine recurring consumer needs with opportunities for product differentiation and distribution-led growth.
Unlike traditional healthcare services, some medical support products can be sold directly to consumers through ecommerce, pharmacies and retail partnerships.
Companies operating in these categories can potentially scale their reach without building a large network of clinics, although they still require product quality, consumer trust, medical credibility and reliable supply chains.
For Lumov, the challenge will be to build a brand that consumers and healthcare professionals trust while expanding sales beyond its early markets.
The Bigger Picture
Lumov’s proposed funding round reflects a broader investment trend in India’s healthcare startup ecosystem, where investors are exploring businesses beyond hospitals, diagnostic services and digital health platforms.
Consumer-facing healthcare products, rehabilitation technologies, specialised medical devices and wellness categories are creating new opportunities for startups to develop differentiated businesses.
The orthopaedic support market may not have the same visibility as mainstream consumer technology, but its products address practical and recurring needs for patients, elderly consumers, athletes and people recovering from injuries.
If Lumov can combine clinical collaboration with effective branding, product quality and accessible distribution, it could establish a stronger position in India’s expanding rehabilitation and orthopaedic products market.
Looking Ahead
Lumov is expected to use its next funding round to strengthen its manufacturing and sales capabilities, develop additional orthopaedic products and expand its reach through online and offline distribution channels. Participation from Peak XV’s Surge programme could also provide access to investor networks and strategic support as the startup scales.
The proposed ₹33 crore investment remains subject to finalisation, but it signals investor interest in building consumer brands around specialised healthcare needs. Lumov’s ability to translate clinical requirements into products that consumers trust and regularly purchase will be central to its growth ambitions.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.



